Mkt Cap$2.24T-0.27%
24h Vol$63.96B
BTC Dom56.1%
ETH Dom9.6%
F&G22Extreme Fear
BTC$62,618.00-0.25% ETH$1,784.25+0.38% USDT$0.9988-0.04% BNB$569.17+0.14% USDC$0.9999+0.01% XRP$1.07-0.61% SOL$75.19-1.62% TRX$0.3249-1.59% FIGR_HELOC$1.03+1.91% HYPE$63.74-2.41% DOGE$0.0723+0.10% USDS$0.99970.00% RAIN$0.0143-0.35% LEO$9.54+0.05% ZEC$507.59-1.85% WBT$54.95-0.04% BTC$62,618.00-0.25% ETH$1,784.25+0.38% USDT$0.9988-0.04% BNB$569.17+0.14% USDC$0.9999+0.01% XRP$1.07-0.61% SOL$75.19-1.62% TRX$0.3249-1.59% FIGR_HELOC$1.03+1.91% HYPE$63.74-2.41% DOGE$0.0723+0.10% USDS$0.99970.00% RAIN$0.0143-0.35% LEO$9.54+0.05% ZEC$507.59-1.85% WBT$54.95-0.04%
News

Weight Loss Drugs

Total Stories
3
Section
Weight Loss Drugs
Why Is Novo Nordisk (NVO) Stock Down 13% Premarket? Trial Fails to Match Eli Lilly
Market Analysis

Why Is Novo Nordisk Stock Down 13% Premarket? Trial Fails to Match Eli Lilly

Novo Nordisk stock plunged over 13% in premarket trading after its experimental obesity drug CagriSema failed to prove non-inferiority to Eli Lilly's tirzepatide in the REDEFINE 4 trial.

Tim FriesFeb 23, 20264 min read